| Description | Isbogrel (CV4151) is a small molecule thromboxane A2 synthase (TXA2 synthase) inhibitor that can be used to study cardiac arrhythmias, transient ischemic attacks and thrombosis. |
| In vivo | CV-4151 significantly inhibited photochemically induced MCA thrombosis by oral (1 and 10 mg/kg) and intravenous (1 mg/kg) administration.[2] CV-4151 (10 mg/kg, p.o.), furthermore, significantly reduced the infarct size and inhibited the increase in lactate content. CV-4151 might be a useful drug for the treatment of cerebral thrombosis and for the prevention of cerebral infarction.[2] |
| Synonyms | CV4151, CV-4151, CV 4151 |
| molecular weight | 281.35 |
| Molecular formula | C18H19NO2 |
| CAS | 89667-40-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (195.49 mM) |
| References | 1. Terashita Z, et al. Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: modulation of the antiplatelet action and prostanoid metabolism by rat aortic rings. J Lipid Mediat Cell Signal. 1996 Jan;13(1):1-8. 2. Imura Y, et al. Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. Thromb Res. 1995 Jul 1;79(1):95-107. 3. Asai F, et al. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate. Arzneimittelforschung. 1991 May;41(5):506-10. 4. Terashita Z, et al. Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury. Thromb Res. 1995 Mar 1;77(5):411-21. |